RU2253674C2 - Treatment biological preparation against animal endometritis - Google Patents

Abstract

FIELD: biotechnology, medicine, veterinary, in particular drug for treatment and prevention of cow endometritis.

SUBSTANCE: claimed biological preparation contains dry biomass of strain Bifidobacterium pseudolongum N 533 and strain Lactobacillus salivarius N 117. Strains are cultivated separately on broth providing accumulation of necessary biomass. Biomass is concentrated by centrifugation and mixed with safety medium in ratio of 1:1-1:2, respectively. Obtained suspensions of B. pseudolongum N 533 and L. salivarius N 117 biomasses are blended in equal amounts, bottled into 2-4 ml bijous and dried.

EFFECT: preparation with high adhesion, antagonistic activity to opportunistic and pathogenic microflora and increased therapeutical effectiveness.

1 tbl, 2 ex

Description

The invention relates to biotechnology, microbiology, the production of probiotics and can be used in veterinary medicine.

The solution to the problem of endometritis of the uterine livestock of cattle is promising in the development of livestock. There is information about the leading role of pathogenic and conditionally pathogenic microflora in the development of pathology; therefore, various chemotherapeutic agents and antibiotics are used in the treatment of endometritis. The results of treatment depend on the drug resistance of pathogens [1].

Another direction in the prevention and treatment of cow endometritis is indicated, which provides for the use of antagonistically active microorganisms to pathogens. It is known the use of dry biosan containing live cultures of microorganisms Lactobacillus plantarum, Lactobacillus buchneri. However, these lactic acid bacteria and a preparation prepared on their basis do not contain the necessary number of viable cells for an effective therapeutic and prophylactic effect [2].

The closest analogue in technical essence to the invention is a preparation comprising microorganisms of the species: Bifidobacterium bifidum, Lactobacillus acidophilus, Lactobacillus fermenti. The drug is used as a dry mixture [3].

The disadvantage of this method is the use of strains of B. bifidum, L. acidophilus isolated from the human intestine. Strains exhibit weak enzymatic and biochemical properties, are not sufficiently resistant to a number of antibiotics.

The objective of the invention is to obtain a drug of probiotic action in the prevention and treatment of endometritis of cows.

The technical result of the invention is to increase the therapeutic efficacy of the drug due to the inclusion of microorganisms with high adhesiveness and active biological properties in the preparation.

The essence of the invention lies in the fact that the proposed biological product includes the following strains: Bifidobacterium pseudolonqum No. 533 and Lactobacillus salivarius No. 117 isolated at the Department of Epizootology of Microbiology of the Vologda State Dairy Academy named after N.V. Vereshchagin.

Strain B. pseudolonqum No. 533 isolated from the contents of the genital tract of healthy women.

The cells of strain B. pseudolonqum No. 533 are gram-positive bacilli, immobile, do not form spores, and tend to branch when grown on hepatic agar. The strain has a high biochemical activity and accumulates the necessary microbial mass in various environments. The strain inhibits the growth of pathogenic and opportunistic microorganisms.

Strain L. salivarius No. 117 was isolated from the intravaginal contents of healthy cows using agarized MPC media, streptomycete agar with glucose, and streptomycete agar with glycerin when thermostated at (37 ± 1) ° С for 72 hours. Cells of strain L. salivarius No. 117 have a rod-shaped form, do not form spores, are motionless, gram-positive, exhibit enzymatic properties with the formation of lactic, acetic, succinic acids and actively multiply on hydrolyzate-dairy medium, casein-yeast medium and whey [4]. When growing on nutrient media, it accumulates the necessary biomass, which allows its use in the technological process. Strain L. salivarius No. 117 has a pronounced antagonistic activity against pathogenic microflora: growth retardation zone of the Staph test cultures. aureus is 28 ± 1.7 mm; E. coli 25 ± 1.3 mm; B. cereus 26 ± 4.1 mm; S. dublin 27 ± 2.4 mm. The strain exhibits high resistance to tetracycline antibiotics and chloramphenicol.

Example 1. A biological product containing the strains: B. pseudolonqum No. 533 and L. salivarius No. 117, is produced on the basis of the bacterial mass by separate cultivation of the strains on liquid nutrient media used for growing bifidobacteria and lactobacilli. Within 12-16 hours of cultivation at a temperature of (37 ± 1) ° С, the biomass yield reaches at least 10 billion living cells in 1 ml of culture medium. The grown cultures are cooled to 6-10 ° C and subjected to centrifugation. The resulting biomass is mixed with a protective medium: sucrose - 10%, calcium gluconate - 1.5-2%, ascorbic acid - 1%, and the ratio of biomass and protective environment is 1: 1-1: 2. The prepared suspensions are poured into vials of 2 ml or 4 ml and dried at a temperature of (58 ± 2) ° C for 2-4 hours. The content of viable cells of bifidobacteria and lactic acid bacilli is up to 200 billion cells per 1 g of the drug.

In one bottle contains at least 20 billion cells in an equal amount of each strain.

Example 2. As a biological model for testing a biological product, cows are used after calving in a farm endowed with endometritis.

Control are animals to which the drug is not prescribed, prevention and treatment are carried out by the traditional method.

The drug is injected into the uterine cavity, previously dissolved in boiled and chilled to 37 ° C water in a single dose, which is in one bottle, twice, after 24-48 hours. For therapeutic purposes, the drug is administered in a double dose twice a day until recovery.

Take into account the number of animals without dysfunction after calving with the introduction of a biological product, of which the number of cases, the number of fertilized after the first mating, the duration of the disease in comparison with the control groups.

The data are presented in the table.

From the table it follows that the drug, including strains of B. pseudolonqum No. 533 and L. salivarius No. 117, has a preventive and therapeutic effect when tested in animals and reduces the incidence of endometritis.

SOURCES OF INFORMATION TAKEN INTO ACCOUNT

1. Trishkina E.T., Galushko L.Kh. Microbial factor in the etiology of postpartum endometritis of cows. / Veterinary medicine. - 1985. - No. 11. - p. 52-53.

2. Guardians K.A., Ivanovsky A.A., Vepreva N.S. Dry biosan with endometritis in cows. / Veterinary medicine. - 1994. - No. 2 - p. 39-40.

3. Patent RU 2182008, 2000

4. RF patent 1712401 A1, 1992

Table Groups of animals Accounted for Experienced with the use of a biological product Control using traditional methods indicators Preventive action group I Therapeutic effect II group Preventive action of group III Therapeutic effect IV group 1 2 3 4 5 1. The total number in the group: goal. 298 55 120 48 2. Of these, without impaired function after calving: goal. 264 - 74 - % 88.6 - 61.7 - 3. The disease arose: goal. 34 - 46 - % 11,4 - 38.3 - 4. The number of fertilized after the first mating: goal. 287 51 82 31 % 96.3 92.7 68.3 64.6 5. Duration of the disease: days. - 8 - thirteen

Claims (1)

Biological product of therapeutic and prophylactic action in animal endometritis, containing dry biomass of strains of Bifidobacterium pseudolongum No. 533 and Lactobacillus salivarius No. 117, stored in the collection of the Museum of Pure Culture of Microorganisms of the Vologda State Dairy Academy named after N.V. Vereshchagin, in equal quantities.